 Patients receive etanercept subcutaneously SC twice weekly during weeks 1 and 2 and azacitidine SC or intravenously IV over 10-40 minutes on days 1-7. Treatment repeats every 28 days for at least 3 courses. Treatment continues in the absence of disease progression or unacceptable toxicity. 